ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,110 GBX | -0.46% |
|
-2.10% | +14.25% |
| 17/05 | Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial | RE |
| 16/05 | AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 51.56B 4,293B | Sales 2025 * | 55.37B 4,610B | Capitalization | 239B 19,860B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.62B 718B | Net income 2025 * | 10.3B 858B | EV / Sales 2024 * | 5.03 x |
| Net Debt 2024 * | 20.65B 1,719B | Net Debt 2025 * | 14.01B 1,166B | EV / Sales 2025 * | 4.56 x |
| P/E ratio 2024 * |
28
x | P/E ratio 2025 * |
23.4
x | Employees | 89,900 |
| Yield 2024 * |
2% | Yield 2025 * |
2.11% | Free-Float | 96.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | -0.46% | ||
| 1 week | -2.10% | ||
| Current month | +0.40% | ||
| 1 month | +10.63% | ||
| 3 months | +16.24% | ||
| 6 months | +18.03% | ||
| Current year | +14.25% |
1 week
12 068.00
12 406.00
1 month
11 004.0012 488.00
Current year
9 461.0012 488.00
1 year
9 461.0012 488.00
3 years
7 870.0012 488.00
5 years
5 739.0012 488.00
10 years
3 680.0012 488.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01/12/01 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01/21/01 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 01/17/01 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 01/13/01 |
Philip Broadley
BRD | Director/Board Member | 63 | 27/17/27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 200 M€ | +17.40% | ||
| 5.17% | 17 M€ | +8.10% | - | |
| 4.89% | 693 M€ | +11.99% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 12,110 | -0.46% | 1,676,790 |
| 16/24/16 | 12,166 | -0.05% | 1,649,252 |
| 15/24/15 | 12,172 | -0.60% | 1,473,537 |
| 14/24/14 | 12,246 | -0.58% | 6,023,670 |
| 13/24/13 | 12,318 | -0.42% | 4,031,899 |
Delayed Quote London S.E., May 17, 2024 at 09:05 pm IST
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.9
USD
Average target price
167.7
USD
Spread / Average Target
+9.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.25% | 239B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B | |
| -0.52% | 162B |
- Stock Market
- Equities
- AZN Stock
